Phibro Animal Health (NASDAQ:PAHC) CEO Sells $612,154.16 in Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 14,687 shares of the business’s stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $41.68, for a total value of $612,154.16. Following the transaction, the chief executive officer owned 29,838 shares in the company, valued at approximately $1,243,647.84. This trade represents a 32.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Jack Bendheim also recently made the following trade(s):

• On Thursday, January 22nd, Jack Bendheim sold 13,158 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.98, for a total value of $552,372.84.
• On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.02, for a total transaction of $117,338.64.
• On Wednesday, January 14th, Jack Bendheim sold 3,651 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.53, for a total transaction of $147,975.03.
• On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.32, for a total transaction of $304,456.32.
• On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.16, for a total transaction of $8,554.08.
• On Wednesday, January 7th, Jack Bendheim sold 328 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total transaction of $13,149.52.
• On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.93, for a total value of $235,429.36.
• On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.19, for a total value of $51,764.72.
• On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.06, for a total value of $141,011.20.
• On Wednesday, December 3rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.77, for a total value of $143,510.40.

Phibro Animal Health Stock Performance

PAHC traded down $0.34 during trading on Thursday, reaching $41.61. 212,999 shares of the company’s stock were exchanged, compared to its average volume of 197,450. The stock has a market capitalization of $1.69 billion, a P/E ratio of 25.07, a price-to-earnings-growth ratio of 1.16 and a beta of 0.79. Phibro Animal Health Corporation has a 1 year low of $16.16 and a 1 year high of $46.42. The company’s fifty day simple moving average is $40.28 and its 200-day simple moving average is $37.41. The company has a debt-to-equity ratio of 2.32, a current ratio of 3.09 and a quick ratio of 1.35.

Phibro Animal Health (NASDAQ:PAHC) last posted its earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.15. The company had revenue of $363.89 million during the quarter, compared to the consensus estimate of $345.44 million. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. As a group, research analysts predict that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th were issued a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend was Wednesday, November 26th. Phibro Animal Health’s payout ratio is 28.92%.

Institutional Trading of Phibro Animal Health

Several large investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Phibro Animal Health by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock worth $260,000 after purchasing an additional 546 shares in the last quarter. Millennium Management LLC grew its holdings in Phibro Animal Health by 74.3% in the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock valued at $7,733,000 after buying an additional 154,281 shares in the last quarter. Jane Street Group LLC grew its holdings in Phibro Animal Health by 65.3% in the 1st quarter. Jane Street Group LLC now owns 33,917 shares of the company’s stock valued at $724,000 after buying an additional 13,404 shares in the last quarter. Voya Investment Management LLC increased its stake in shares of Phibro Animal Health by 44.3% in the 1st quarter. Voya Investment Management LLC now owns 31,894 shares of the company’s stock worth $681,000 after acquiring an additional 9,796 shares during the last quarter. Finally, Financial Management Professionals Inc. purchased a new position in shares of Phibro Animal Health during the 2nd quarter worth $32,000. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on PAHC shares. JPMorgan Chase & Co. increased their target price on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Finally, Zacks Research upgraded Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $31.40.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.